The Latest Breaking News from HUM

Humana stock has underperformed compared to the healthcare services group, but analysts remain fairly bullish about its prospects.

Although Humana has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Another historic session is unfolding on Wall Street, where every major index surged to new records by midday trading on Friday, even as Washington's shutdown dragged into its third day.

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

While Humana has notably underperformed the broader healthcare sector over the past year, it has outperformed recently, and analysts remain optimistic about the stock’s prospects.

While Humana stock seems to be regaining momentum lately, it is still underperforming the broader market, keeping analysts cautiously optimistic about its prospects.

As the healthcare landscape evolves with new legislation and shifting demographics, Humana Inc. (NYSE:HUM) is adapting to these changes through strategic adjustments. This adaptability is reflected in their second-quarter earnings report, which exceeded analysts’ expectations despite a decline in adjusted EPS compared to last year.

Humana Inc. NYSE: HUM) on Tuesday announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians associated with prior authorization.

Shares of Humana Inc. (NYSE:HUM) are trading lower Friday after the company lost a legal battle over Medicare bonus payments.